Generex has an interesting idea of what "clean" means

New Post Public Reply Private Reply Replies (1) Message Board
docj Beasley #31815
367
Generex has an interesting idea of what "clean" means relative to NGIO. Here is a year old letter from the SEC.

Joseph Moscato
Chief Executive Officer
NuGenerex Immuno-Oncology, Inc.
10102 USA Today Way
Miramar, FL 33025
Re: NuGenerex Immuno-Oncology, Inc.
Amendment No. 1 to Registration Statement on Form 10-12G
Filed June 12, 2020
File No. 000-56153
Dear Mr. Moscato:
We have reviewed your filing and have the following comments. In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.
Please respond to these comments within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comments apply to your facts and circumstances, please tell us why in your response.
After reviewing your response and any amendment you may file in response to these
comments, we may have additional comments.
Amendment No. 1 to Registration Statement on Form 10-12G
Introductory Comment, page 3
1. Please revise to clarify that the registration statement is effective and clarify your
reporting status.
Item 1. Business
AE37 – Ii-Key/HER2/neu Hybrid Immunotherapeutic Vaccine, page 4
2. We note your disclosure in this section that you are currently developing AE37 for the
treatment of cancer, including breast, bladder, prostate, and potentially other
indications yet you state on page 13 that your Phase II clinical study using AE37 in
combination with Keytruda for treatment of metastatic triple negative breast cancer is
your only ongoing research and development project. Please revise or advise. In that
regard, we note your response to our prior comment 4 that you are waiting to see
FirstName LastNameJoseph Moscato
Comapany NameNuGenerex Immuno-Oncology, Inc.
July 7, 2020 Page 2
FirstName LastName
Joseph Moscato
NuGenerex Immuno-Oncology, Inc.
July 7, 2020
Page 2
whether Shenzhen is successful in achieving positive results in the prostate cancer
development program before determining how to proceed. Accordingly, please revise to
disclose, if true, that you are not in the process of developing AE37 for prostate cancer as
stated on page 4.
3. We note your response to our prior comments 2 and 3. Please revise to disclose the term
and the termination provisions for each of the Merck, NSABP and Shenzhen agreements.
Please also indicate whether the royalty term under the Shenzhen agreement is the same as
the term of the agreement.
4. We note your response to our prior comment 8, but we do not see any disclosure
concerning the failure to achieve the primary endpoint which prevented moving to a Phase
III trial of AE37 in breast cancer. Please revise or advise.
5. We note your disclosure that the primary and secondary endpoints were met in the 2006
and 2007 trials for AE37. Please provide the data from the trials that support these
statements and disclose how many subjects were in the 2006 trial.
6. We note your response to our prior comment 5 and reissue in part. Please revise to clarify
the next steps for each of your product candidates, including how much funding you will
need, what steps remain to achieve regulatory approval and the planned timeline.
7. Please revise the disclosure on page 5 to explain your basis for the statement that "funding
for the development of a vaccine of SARS-CoV-2 virus is in advanced discussions and
currently expected that the development costs will be borne by the U.S. and foreign
government agencies."
Clinical Development Plans for Ii-Key Immunotherapeutic Peptides, page 6
8. We note your response to our prior comment 9. Please revise to provide the detail from
your response that the discussions with the major oncology research centers are currently
confidential, and the clinical trials are in the planning stages.
Competition, page 7
9. We note your response to our prior comment 11. Please revise to disclose, if true, that
NGIO has never received regulatory approval for a product candidate or had commercial
sales.
Note 2- Summary of Significant Accounting Policies
Research and Development Costs, page F-8
10. We note from your response and revised disclosures to comment 21 that you completed a
Phase IIb trial of AE37 in combination with GM-CSF in November of 2019. Please
address the following:
• Clarify in the filing if the trial which was completed, as discussed on page 4, is the
FirstName LastNameJoseph Moscato
Comapany NameNuGenerex Immuno-Oncology, Inc.
July 7, 2020 Page 3
FirstName LastName
Joseph Moscato
NuGenerex Immuno-Oncology, Inc.
July 7, 2020
Page 3
same trial in which costs were incurred for AE37 in combination with Keytruda as
disclosed on page 13 in which you incurred $251,459 of costs. If not, please tell us
where the costs for AE37 in combination with GM-CSF were recorded in your
financial statements and revise your MD&A as necessary to discuss the costs
incurred.
• You state on page 5 that "based on the results from the Phase II trial described above,
NGIO entered into a Clinical Trial Collaboration and Supply Agreement" on June 28,
2017 with Merck. Since the Phase IIb trial was not completed until November of
2019. Please clarify in the filing what results you are referring to which resulted in
the collaboration agreement with Merck in 2017.
11. We acknowledge your response and revised disclosures to comment 20. We believe the
significant terms of each material agreement are required to be presented in the filing such
as the rights and obligations of each party, including any significant milestone payments
paid/received to date and aggregate potential milestones and the triggering factors thereof,
the royalty percentages or a range, profit sharing, and termination clauses. For instance, it
does not appear sufficient to omit disclosure of the termination provision in the agreement
with Merck because you do not believe an accrual for a liability is warranted. Please
revise your disclosure accordingly.
Note 3 - Commitments and Contingencies
Payable to Foundation, page F-10
12. We note from your response and revised disclosures to comment 22 that effective August
1, 2015, you capitalized all outstanding unpaid interest on the outstanding balance. Please
explain to us your basis for capitalizing the unpaid interest on this payable.
Exhibits
13. Please file an executed copy of Exhibit 10.3. In this regard, we note that it is unclear
whether the counterparty signed the agreement.
FirstName LastNameJoseph Moscato
Comapany NameNuGenerex Immuno-Oncology, Inc.
July 7, 2020 Page 4
FirstName LastName
Joseph Moscato
NuGenerex Immuno-Oncology, Inc.
July 7, 2020
Page 4
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
You may contact Eric Atallah at 202-551-3663 or Mary Mast at 202-551-3613 if you
have questions regarding comments on the financial statements and related matters. Please
contact Ada D. Sarmento at 202-551-3798 or Joe McCann at 202-551-6262 with any other
questions.


Sincerely,
Division of Corporation Finance
Office of Life Science

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 147

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 114

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 19

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 139

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading

Top 5 Most Recently Viewed Articles

Trinseo Announces New Dividend Amid Strategic Changes Ahead

Updated Category News Views 225

Trinseo Approves Dividend for Shareholders Trinseo (NYSE: TSE), a prominent provider of specialty material solutions, has recently announced a quarterly dividend approved by its Board of Directors. The dividend declared stands at $0.01 per share, set to be distributed on a future date, offering a slight financial incentive for shareholders. To be eligible, shareholders...

Continue Reading
2026 Mighty 25: Celebrating Military Community Leaders

Updated Category News Views 26

A Spotlight on Unsung Heroes Tampa, Florida, just got a little mightier as We Are The Mighty rolls out the red carpet for the 2026 Mighty 25. This annual roll call, backed by CareSource Military & Veterans™, shines a light on veterans, military spouses, creators, entrepreneurs, and change agents defying the status quo. They are redefining impact across the military...

Continue Reading
Rubrik Inc Soars as Earnings Beat Expectations

Updated Category News Views 238

Rubrik Inc's Recent Stock Surge Rubrik, Inc. (NYSE: RBRK) has recently captured the attention of the market as its shares have risen over 20% following an impressive report of fourth-quarter earnings. The company exceeded expectations in both profitability and revenue, which undoubtedly prompted a wave of investor optimism. Financial Performance Highlights For the latest...

Continue Reading
Sanofi’s Amlitelimab Achieves Key Study Goals for Eczema Treatment

Updated Category News Views 284

Sanofi’s Amlitelimab Revolutionizes Atopic Dermatitis Treatment In an exciting development for patients suffering from atopic dermatitis, Sanofi's amlitelimab has met all primary and key secondary endpoints in the pivotal COAST 1 phase 3 study, targeting both adults and adolescents. This innovative medication demonstrated meaningful efficacy in terms of skin clearance...

Continue Reading
Alphamin Resources Corp: Board Changes and Future Outlook

Updated Category News Views 168

Leadership Changes at Alphamin Resources Corp Alphamin Resources Corp., a prominent player in the mining sector, recently shared significant news regarding its board of directors. The company announced the resignation of Mr. Rudolf Pretorius as a director. This change marks a pivotal moment in the company’s leadership structure, as Mr. Pretorius had been with the board...

Continue Reading